Insulet Corporation - Common Stock (PODD)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Apr 2, 2026Investment Snapshot
- Trading 429% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 14.7% — below-average profitability
- Revenue growing at 31% annually
Insulet Corporation - Common Stock (PODD) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $14.6 billion . Key value metrics: P/E ratio 65.4, P/B ratio 9.62, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Insulet Corporation - Common Stock — Fundamental Analysis Summary
Insulet Corporation - Common Stock (PODD) is currently trading 429% above its Graham Number of $39.17, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 65.4x.
On financial health, PODD shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 14.7% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.92.
StockPik's composite Value Score for PODD is 44/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PODD reports a high gross margin of 70.8% (sector average: 33.5%) and a solid operating margin of 16.8%.
PODD shows revenue growing at 31% year-over-year, with earnings declining at 41%.